367 related articles for article (PubMed ID: 25261968)
1. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
2. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
[TBL] [Abstract][Full Text] [Related]
3. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
4. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
[TBL] [Abstract][Full Text] [Related]
5. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.
Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T
J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.
Li M; Li JY; Zhao AL; Gu J
Oncology; 2007; 73(1-2):52-7. PubMed ID: 18334831
[TBL] [Abstract][Full Text] [Related]
7. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
8. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of the mesorectal extension of rectal cancer: a Japanese multi-institutional study.
Shirouzu K; Akagi Y; Fujita S; Ueno H; Takii Y; Komori K; Ito M; Sugihara K;
Ann Surg; 2011 Apr; 253(4):704-10. PubMed ID: 21475010
[TBL] [Abstract][Full Text] [Related]
10. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
Rini B; Goddard A; Knezevic D; Maddala T; Zhou M; Aydin H; Campbell S; Elson P; Koscielny S; Lopatin M; Svedman C; Martini JF; Williams JA; Verkarre V; Radulescu C; Neuzillet Y; Hemmerlé I; Timsit MO; Tsiatis AC; Bonham M; Lebret T; Mejean A; Escudier B
Lancet Oncol; 2015 Jun; 16(6):676-85. PubMed ID: 25979595
[TBL] [Abstract][Full Text] [Related]
11. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
[TBL] [Abstract][Full Text] [Related]
12. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer.
Wong JC; Chan SK; Schaeffer DF; Sagaert X; Lim HJ; Kennecke H; Owen DA; Suh KW; Kim YB; Tai IT
Clin Cancer Res; 2011 Jun; 17(12):4167-76. PubMed ID: 21531813
[TBL] [Abstract][Full Text] [Related]
13. Unexpected rectal cancer after TEM: outcome of completion surgery compared with primary TME.
van Gijn W; Brehm V; de Graaf E; Neijenhuis PA; Stassen LP; Leijtens JW; Van De Velde CJ; Doornebosch PG
Eur J Surg Oncol; 2013 Nov; 39(11):1225-9. PubMed ID: 23972571
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
[TBL] [Abstract][Full Text] [Related]
17. Gene signature is associated with early stage rectal cancer recurrence.
Kalady MF; Dejulius K; Church JM; Lavery IC; Fazio VW; Ishwaran H
J Am Coll Surg; 2010 Aug; 211(2):187-95. PubMed ID: 20670856
[TBL] [Abstract][Full Text] [Related]
18. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
[TBL] [Abstract][Full Text] [Related]
19. Effect of adjuvant chemotherapy on recurrence-free survival varies by neo-adjuvant treatment in patients with stage III rectal cancer.
van Erning FN; Rutten HJ; van den Berg HA; Lemmens VE; van Halteren HK
Eur J Surg Oncol; 2015 Dec; 41(12):1630-5. PubMed ID: 26437853
[TBL] [Abstract][Full Text] [Related]
20. Factors that influence the adequacy of total mesorectal excision for rectal cancer.
Jeyarajah S; Sutton CD; Miller AS; Hemingway D;
Colorectal Dis; 2007 Nov; 9(9):808-15. PubMed ID: 17441969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
